Created Date: July 07, 2009
Description: Dr. Michael Hallek discusses the benefits and challenges of using mouse models such as TCL1, NOD/SCID, and NZB in CLL drug trials and studies attempting to isolate potential cancer stem cells. Then, he discusses proposed trials comparing the effectiveness of various drug combinations and, hypothetically, how one might develop a study to determine whether certain types of chemical agents are linked to CLL.
Creator: Gerald Marti
Contributor: Michael Hallek
Series: Hallek Oral Histories
Rights: This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.